Husic-Selimovic Azra, Custovic Nerma, Sivac Nadza, Glamoclija Una, Sukalo Aziz, Mehic Meliha
Clinic of Gastroenterohepatology, Clinical Centre University of Sarajevo, Sarajevo, Bosnia and Herzegovina.
Bosnalijek d.d., Sarajevo, Bosnia and Herzegovina.
Mater Sociomed. 2022 Dec;34(4):267-271. doi: 10.5455/msm.2022.34.267-271.
Acute gastroenteritis remains an extremely common problem among the general population. In Western countries, an average person will probably face one or two episodes of gastrointestinal infections every year.
The aim of this study was to compare the efficacy of nifuroxazide and probiotic preparation containing lactic acid bacteria in the treatment of acute diarrheal syndrome.
The study was prospective, comparative study. Patients who suffered from acute infective diarrhoea for ≤72 hours and had ≥3 unformed stools per day, with no administration of antibiotics during 10 days before enrolment were divided into two groups: nifuroxazide group and the lactic acid probiotic group. All patients received therapies four times a day for three days. Data was collected at the baseline visit (before the initiation of the treatment) and two follow-up examinations on the third and seventh day from the treatment start.
The study included 61 patients, 36 in nifuroxazide group and 25 in probiotic group. Nifuroxazide group compared to probiotic group showed faster improvement of patients' condition with lower number of stools three and seven days after therapy start (p=0.001 and p<0.001 respectively) and faster stool consistency normalization. On the seventh day from therapy start medium mushy stool consistency was observed in the majority of patients in nifuroxazide group (n=31, 86%) and only in small number of patients in probiotic group (n=5, 20%). Patients were feeling better and there was a trend of reporting better therapy efficacy in nifuroxazide group. Subjective assessment of therapy tolerability was also better in nifuroxazide group. Compliance to therapy and recommended dietary regime was similar between groups and there were no significant differences between groups regarding age, gender, elevated body temperature, abdominal pain, cramps, nausea and vomiting.
Although probiotics are sometimes used in the treatment of acute diarrheal syndrome, nifuroxazide has better efficacy and greater patients' satisfaction. Nifuroxazide can be recommended as the first choice empirical treatment in adult patients with the acute diarrheal syndrome.
急性肠胃炎在普通人群中仍然是一个极其常见的问题。在西方国家,普通人每年可能会面临一到两次胃肠道感染。
本研究旨在比较硝呋太尔和含乳酸菌的益生菌制剂治疗急性腹泻综合征的疗效。
本研究为前瞻性比较研究。将发病≤72小时、每日有≥3次不成形大便且在入组前10天内未使用抗生素的急性感染性腹泻患者分为两组:硝呋太尔组和乳酸菌益生菌组。所有患者每天接受4次治疗,持续3天。在基线访视(治疗开始前)以及治疗开始后第3天和第7天的两次随访检查中收集数据。
该研究纳入了61例患者,硝呋太尔组36例,益生菌组25例。与益生菌组相比,硝呋太尔组患者病情改善更快,治疗开始后第3天和第7天的大便次数更少(分别为p = 0.001和p < 0.001),大便性状恢复正常更快。在治疗开始第7天,硝呋太尔组大多数患者(n = 31,86%)的大便性状为中度糊状,而益生菌组只有少数患者(n = 5,20%)如此。硝呋太尔组患者感觉更好,且报告的治疗效果有更好的趋势。硝呋太尔组对治疗耐受性的主观评估也更好。两组间对治疗和推荐饮食方案的依从性相似,在年龄、性别、体温升高、腹痛、痉挛、恶心和呕吐方面两组间无显著差异。
虽然益生菌有时用于治疗急性腹泻综合征,但硝呋太尔疗效更好,患者满意度更高。硝呋太尔可推荐作为成年急性腹泻综合征患者的首选经验性治疗药物。